Abstract
Purpose
To evaluate the effect of Bog Bilberry (Vaccinium uliginosum) extract in eyes with early age-related macular de-generation (AMD).
Methods
Forty- four eyes of forty four patients with early AMD were included in this randomized, double-blinded, and pla-cebo-controlled study. All participants were randomly assigned to either the placebo group (n = 24), or the bog bilberry ex-tract group (n = 20). Before drug administration, an ophthalmic examination which included slit lamp microscopy, best cor-rected visual acuity, and intraocular pressure was performed, and repeated 1and 3 months after treatment. Objective scat-ter index, glare and tear film break-up time were checked by Optical Quality Analysis System (OQAS, Visiometrics, Spain) and drusen volume, central macular thickness, and RPE and IS/OS junction thickness were investigated with spectral-do-main optical coherence tomography (Spectralis, Heidelberg, Germany).
References
1. Friedman DS, O'Colmain BJ, Muñoz B. . Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122:564–72.
2. Youn DJ, Oh HS, Yu HG, Song SJ. The prevalence of vitreoretinal disease in a Screened Korean population 50 years and older. J Korean Ophthalmol Soc. 2009; 50:1645–51.
3. Park KH, Song SJ, Lee WK. . The results of nation-wide regis-try of age-related macular degeneration in Korea. J Korean Ophthalmol Soc. 2010; 51:516–23.
4. Kinnunen K, Petrovski G, Moe MC. . Molecular mechanisms of retinal pigment epithelium damage and development of age-re-lated macular degeneration. Acta Ophthalmol. 2012; 90:299–309.
5. Evans J. Antioxidant supplements to prevent or slow down the pro-gression of AMD: a systematic review and meta-analysis. Eye (Lond). 2008; 22:751–60.
6. AREDS group. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case- control study: Report No.22. Arch Ophtalmol. 2007; 125:1225–32.
7. Sin HP, Liu DT, Lam DS. Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration. Acta Ophthalmol. 2013; 91:6–11.
8. Määttä-Riihinen KR, Kamal-Eldin A, Mattila PH. . Distribution and contents of phenolic compounds in eighteen Scandinavian berry species. J Agric Food Chem. 2004; 52:4477–86.
9. Lätti AK, Jaakola L, Riihinen KR, Kainulainen PS. Anthocyanin and flavonol variation in bog bilberries (Vaccinium uliginosum L.) in Finland. J Agric Food Chem. 2010; 58:427–33.
10. Kim YH, Bang CY, Won EK. . Antioxidant activities of Vaccinium uliginosum L. extract and its active components. J Med Food. 2009; 12:885–92.
11. AREDS group. The Age-Related Eye Disease Study (AREDS): de-sign implications. AREDS report No. 1. Control Clin Trials. 1999; 20:573–600.
12. Kim SH, Park JY, Park TK. . Use of spectral-domain optical coherence tomography to analyze macular thickness according to refractive error. J Korean Ophthlamol Soc. 2011; 52:1286–95.
13. Schuman SG, Koreishi AF, Farsiu S. . Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral domain optical coherence tomography. Ophthalmology. 2009; 116:488–96.e2.
14. Canton VM, Quiroz-Mercado H, Velez-Montoya R.. 16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging. 2011; 42:468–73.
15. Augustin A. Triple therapy for age-related macular degeneration. Retina. 2009; 29:(6 Suppl). S8–11.
16. Nishimura T, Machida S, Harada T, Kurosaka D. Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. Clin Ophthlmol. 2012; 6:1073–82.
17. Blodi BA. Nutritional supplements in the prevention of age-related macular degeneration. Insight. 2004; 29:15–6; quiz 17-8.
18. Kowluru RA, Zhong Q. Beyond AREDS: Is there a place for anti-oxidant therapy in the prevention/treatment of eye disease? Invest Ophthlmol Vis Sci. 2011; 52:8665–71.
19. Congdon N, O'Colmain B, Klaver CC. . Causes and prevalence of visual impairment among adults in the Unites States. Arch Ophthlmol. 2004; 122:477–85.
20. Age-Related Eye Disease Study Research Group . Risk factors as-sociated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study Report Number 3. Ophthalmology. 2000; 107:2224–32.
21. Zeng S, Hernández J, Mullins RF. Effects of antioxidant compo-nents of AREDS vitamins and zinc ions on endothelial cell activation: implications for macular degeneration. Invest Ophthalmol Vis Sci. 2012; 53:1041–7.
22. Park KH, Song SJ, Lee WK. . The results of nation-wide regis-try of age-related macular degeneration in Korea. J Korean Ophthalmol Soc. 2010; 51:516–23.
23. Christensen UC, Kroyer K, Thomasdsen J, el al. Normative data of outer photoreceptor layer thickness obtained by software image en-hancing based on Stratus optical coherence tomography images. Br J Ophthalmol. 2008; 92:800–5.
24. Chan A, Duker JS, Ishikawa H. . Quantification of photo-receptor layer thickness in normal eyes using optical coherence tomography. Retina. 2006; 26:655–60.
25. Jackson GR, Owsley C, Curcion CA. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev. 2002; 1:381–96.
26. Kanai K, Abe T, Murayama K, Yoneya S. Retinal thickness and changes with age. Nihon Ganka Gakkai Zasshi. 2002; 106:162–5.
27. Kang JH, Kim SA, Song UG, Yoon HS. Macular thickness changes with age in normal subjects measured by optical coherence tomography. J Korean Ophthalmol Soc. 2004; 45:592–8.